Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33770460/
The introduction of novel targeted agents and immunotherapeutic modalities into the treatment of B-cell lymphomas has drastically shifted the treatment landscape. In diffuse large B-cell lymphoma, recent approvals of CAR T-cell therapy, the antibody-drug conjugate polatuzumab, and the anti-CD19 mono ...
-
Mark FeslerApril 08, 2021We are likely at the tip of the iceberg in regards to immunotherapy as additional car T, nk cell therapy, and bispecific immunotherapy are likely to see expansion and integration into treatment pathways in the coming months and years ....